Lilly says oral orforglipron maintained weight after switch from injectables

The wire

1. 01Eli Lilly reported that people who switched from injectable incretin medicines to oral orforglipron maintained their weight loss in what the company calls a first-of-its-kind Phase 3 trial.
2. 02A durable oral switch option would matter for prescribers and telehealth operators managing injection-averse patients and for pharmacies handling incretin supply.
3. 03Detailed endpoint data, magnitude of maintenance and tolerability figures come from the company's announcement; full trial results and regulatory timing have yet to be presented.

From the source

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial